Mary Talley Bowden on ivermectin: what the evidence says · JRE #2335
SUBJECT: IVERMECTIN
The short answer
Bowden claims she treated well over 6,000 patients and that everyone who got early treatment stayed out of the hospital. Bowden offers an uncontrolled personal case series with no comparison group, so a reported 100 percent out-of-hospital rate among self-selected early-treatment patients cannot establish that any treatment worked.
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
So once I knew it was safe, then I started using it and then I found it worked. And then all in all, I treated well over 6,000 patients and everybody that got early treatment stayed out of the hospital.
What the evidence says 01 / RECORD
Bowden offers an uncontrolled personal case series with no comparison group, so a reported 100 percent out-of-hospital rate among self-selected early-treatment patients cannot establish that any treatment worked. The largest randomized, placebo-controlled trials of the ivermectin-based approach she is known for found no benefit: the TOGETHER trial (New England Journal of Medicine, 2022) concluded that early ivermectin did not result in a lower incidence of hospital admission due to progression of COVID-19. The NIH-funded ACTIV-6 trial, including a higher-dose arm (600 micrograms per kilogram for 6 days), likewise found ivermectin did not improve time to recovery and did not reduce hospitalizations or deaths, stating the findings do not support its use in outpatients with COVID-19. Anecdotal outcome counts from a single practice, absent a control group, are not evidence that the treatment prevented hospitalizations. The claim is unsupported by controlled evidence.